Pharmaceutical major Lupin's consolidated net profit for the third quarter of 2016-17 went up by 20.7 per cent, a regulatory filing by the company said here on Thursday.
The company posted a net profit of Rs 633.11 crore during the October-December period compared with Rs 524.56 crore posted during the corresponding period in 2015-16.
"This has been a particularly strong year for our US generic business. We had another strong quarter driven by consistent growth across key markets be it the US, India, Japan, EMEA (Europe, the Middle East and Africa), APAC (Asia Pacific) and Latin America. We have made significant progress on evolving our complex generic pipeline and our stellar compliance record continues," said Nilesh Gupta, Managing Director, Lupin.
--IANS
ag/tsb/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app